Brief: Abbisko Cayman's New Drug Application For Pimicotinib Formally Accepted By U.S. FDA
13/01/2026 10:09
Jan 13 (Reuters) - Abbisko Cayman Ltd 2256.HK: UNIT'S NEW DRUG APPLICATION FOR COLONY-STIMULATING FACTOR 1 RECEPTOR INHIBITOR PIMICOTINIB FORMALLY ACCEPTED BY US FDA Further company coverage: 2256.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Abbisko Medicine
See all newsChina's Abbisko jumps on positive clinical trial results for achondroplasia drug
Brief: Abbisko Cayman Says Unit Completes First Patient Dosing In Phase I Trial Of ABSK211
Brief: Abbisko Cayman Gets IND Clearance From FDA For Oral Small Molecule Pan-Kras Inhibitor ABSK211
HK-listed Abbisko hits 7-week peak on AstraZeneca tie-up
Brief: Abbisko Therapeutics And Astrazeneca Enter A Strategic Collaboration